Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
Official title: Project 1: Targeting HIF2 in Renal Cell Carcinoma
Funded at Ut Southwestern Medical Center · NIH-11400746 · Data updated 2026-11-12
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | August 1, 2016 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $357,521 |
| NIH project number | 5P50CA196516-10 |
| Project ID | NIH-11400746 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with clear cell renal cell carcinoma, especially those whose tumors show high HIF2 activity or biomarker signals.
✕Less likely to help
Patients whose tumors do not depend on HIF2 or who cannot tolerate the therapy may not benefit.
What this research studies
This project focuses on a human kidney cancer driven by a protein called HIF2. Researchers build on prior work showing that drugs can bind HIF2 and disrupt its activity in tumor cells, aiming to translate this into better treatments. The team uses patient-derived tumor models in animals and clinical data from early trials to understand which tumors respond and how resistance may emerge. The goal is to identify biomarkers that predict benefit and to refine therapies that target HIF2 in ccRCC.
Why it matters
Potential benefit: If successful, patients with clear cell renal cell carcinoma could gain targeted therapies that halt tumor growth by disabling a key cancer driver.
How similar studies have gone: Previous work demonstrated safety and activity of HIF2 inhibitors in some ccRCC patients, supporting further development.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Brugarolas, James — Ut Southwestern Medical Center
- Study coordinator: Brugarolas, James
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
How mitochondrial activity and cancer spread are affected by tRNA changes in kidney cancer
This project looks at how specific tRNA modifications influence mitochondrial function and the spread of kidney cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.